Revita Life Sciences

ORTHOPEADICS

There are many Situations exist where current conventional treatments including surgery have not worked very well and biological treatment has proved to be very promising.

  • OSTEOARTHRITIS
  • DELAYED AND NONUNION
  • AVASCULAR NECROSIS

How It Works

1. Therapeutic Angiogenesis:

Necessary for delivery of nutrients & oxygen required for Regeneration.

2. Tissue Rejuvenation:

Growth factors secreted by cells Modulate the Locoregional Milieun.

Promote self-repair of residing tissue cells.

Activate the dormant local regenerative cells of damaged tissue.

3. Differentiation:

These cells are themselves a rich source of progenitor cells

Differentiate in bone or cartilage under optimum conditions.

How It Is Done

Patients are evaluated clinically, radiologically by XRAY, CT or MRI scans.

Patients advised to strictly avoid smoking, drug or alcohol consumption and have a positive lifestyle.

As a day care procedure 120 ml of Bone marrow and 100 ml of fat is aspirated and processed for stem cells isolation. 2 ml of stem cells processed as per GMP is injected directly. 

 

 

  • Intra-articular Injection under ultrasound guidance in OSTEOARTHRITIS.
  • Intralesional at Fracture site under fluoroscopic control in NONUNION.
  • Intralesional in AVN under fluoroscopic control in AVASCULAR NECROSIS.

The procedure is very simple as Intra-articular or Intralesional administration of cells can be done to the target site directly under ultrasound guided or C-ARM fluoroscopic control easily.

What To Expect

OSTEOARTHRITIS OF KNEE:

  • WOMAC values (subsets and total) showed significant improvement from baseline over the course of six months treatment (p < 0.001).
  • The pain free distance covered during a Six-minute walk (6MWD) also significantly improved by 140 feet ((p<.001).
  • Requirement of rescue medication decreased to once a week by 45%.
  • The mean (SD) change for the percentage of painful days was 45.0 (38.7).
  • 25% of patients demonstrated improved cartilage thickness by at least 0.2 mm as against 15% who lost thickness at least by 0.01 mm.
  • 55% of patients showed improved Cell counts (below 500 microliters) in Synovial fluid.

DELAYED AND NONUNION:

  • Accelerates healing, 90% of the patients showed quick healing when used as a supplement with first surgery where a high chance of avascular necrosis and Nonunion exist e.g.-# neck femur/ talus/distal tibia
  • Achieved union in 95% of cases in cases of Delayed union (when X-ray showed no callus in bridging construct or callus in stable construct in 3 -6 months)
  • Healing was seen within 3 months in 80% of the cases of atrophic non-union, failed implants of long bones after autologous bone marrow concentrate.
  • Cell therapy accelerated bone healing in the femur compared to in the tibia.

AVASCULAR NECROSIS OF HEAD FEMUR:

  • Significant reduction in pain in all the patients.

  • Back to work within 6 months after treatment.

  • Avoided the progression of the disease effectively in 90 % of hips with Stage I & II and in 40 % of hips with Stage III & IV disease.

  • 10% of hips with stage 1 and II progressed to Stage III: as compared to 50 % of Control patients progressing to Stage III.

  • 6% of Stage 1 and II of the hips needed Total Hip replacement.

  • 60% of Stage III & IV hips needed Total Hip replacement.

  • The mean volume of necrotic lesion in the Control group increased while volume was reduced in the BM-MNC Group at 24 months.

\

Hip Osteoarthritis

Know More
\

AVASCULAR NECROSIS OF FEMORAL HEAD

Know More
\

Osteoarthritis Knee

Know More